SEC Filings

SEC Filings

Filing date	Description	Form	View
Nov 07, 2016	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001193125-16-761896.pdf 0001193125-16-761896.rtf 0001193125-16-761896.xls
Aug 01, 2017	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001047469-17-004898.pdf 0001047469-17-004898.rtf 0001047469-17-004898.xls
Nov 06, 2017	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001047469-17-006801.pdf 0001047469-17-006801.rtf 0001047469-17-006801.xls
Apr 20, 2018	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-18-025614.pdf 0001104659-18-025614.rtf 0001104659-18-025614.xls
Aug 10, 2018	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-18-051206.pdf 0001104659-18-051206.rtf 0001104659-18-051206.xls
Sep 20, 2018	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-18-057809.pdf 0001104659-18-057809.rtf 0001104659-18-057809.xls
Jul 26, 2019	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001558370-19-006414.pdf 0001558370-19-006414.rtf 0001558370-19-006414.xls
Oct 31, 2022	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-22-112950.pdf 0001104659-22-112950.rtf 0001104659-22-112950.xls
Jan 05, 2024	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-24-001796.pdf 0001104659-24-001796.rtf 0001104659-24-001796.xls
Feb 05, 2008	A statement of beneficial ownership of common stock by certain persons	SC 13G	View HTML 0000950005-08-000016.pdf 0000950005-08-000016.rtf 0000950005-08-000016.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE